STOCK TITAN

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.

In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.

Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.

With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 38th Annual Strategic Decisions Conference on June 1, 2022, at the New York Hilton Midtown. The CEO, Joaquin Duato, will represent the company during a session at 10:00 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
conferences
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) has launched a new Satellite Center for Global Health Discovery in Cape Town, South Africa, as part of its ongoing commitment to combat antimicrobial resistance (AMR). This center, developed in collaboration with the Holistic Drug Discovery and Development (H3D) Centre, aims to address the urgent health challenge posed by multidrug-resistant Gram-negative bacteria. The initiative seeks to enhance Africa's scientific capacity and stimulate local innovation by leveraging the strengths of both organizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) will attend the UBS Global Healthcare Conference on May 24, 2022. Mathai Mammen, Executive Vice President of Pharmaceuticals R&D, will represent the company during a session at 10:00 a.m. ET. Interested investors can access the live webcast and subsequent replay, which will be available approximately 48 hours later, through the Johnson & Johnson website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) reported Q1 2022 sales of $23.4 billion, a 5.0% increase, with operational growth at 7.7%. Adjusted earnings per share rose 3.1% to $2.67, while diluted EPS fell 16.8% to $1.93. The suspension of COVID-19 Vaccine sales guidance reflects a global supply surplus and demand uncertainty, though it won't affect adjusted operational EPS guidance. The Pharmaceutical segment drove growth, particularly from DARZALEX and STELARA. Consumer Health sales declined slightly, impacted by supply constraints, while MedTech saw an 8.6% increase in adjusted operational sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) has declared a 6.6% increase in its quarterly dividend, raising it from $1.06 to $1.13 per share. This marks the 60th consecutive year of dividend increases, reflecting the company's strong financial position and future confidence. The annual dividend now stands at $4.52 per share, up from $4.24. Shareholders can expect the next dividend payment on June 7, 2022, with the record date on May 24, 2022 and ex-dividend date on May 23, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
dividends
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities 2022 Healthcare Conference on May 11 at the Encore Hotel in Las Vegas, Nevada. Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech, will represent the company during a session at 3:40 p.m. ET. Investors can access the conference call and additional information via the Johnson & Johnson website. A replay of the webcast and podcast will be available approximately 48 hours after the live event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences
Rhea-AI Summary

Ventus Therapeutics has appointed Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences, bringing over 25 years of experience in computational methods for drug discovery. Dr. Lobanov will lead the company's computational efforts and enhance the ReSOLVE platform while integrating machine learning and structural biology. His past roles include significant contributions at Johnson & Johnson (NYSE: JNJ) and Labcorp Drug Development (NYSE: LH). Ventus aims to leverage his expertise to optimize drug discovery processes, focusing on challenging protein targets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
management
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) will host a conference call on April 19, 2022, at 8:30 a.m. (ET) to discuss its first-quarter results. The call will be led by Joseph J. Wolk, Chief Financial Officer, and Jessica Moore, Vice President of Investor Relations, along with other executives.

Investors can access the call via webcast at www.investor.jnj.com, with a replay available three hours post-call. The press release will be issued at 6:45 a.m. (ET) on the same day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
conferences
-
Rhea-AI Summary

Revelations have emerged regarding Johnson & Johnson (NYSE: JNJ) funding unethical experiments on prisoners during the 1960s, linking to the ongoing controversy over its talc-based products. The experiments involved primarily African-American inmates and raised concerns about the company’s knowledge of the cancer risks associated with its talc products like Johnson's Baby Powder. With the company attempting to limit jury trials through a bankruptcy move, many cancer victims are now seeking justice through litigation. Legal experts call for new laws to prevent corporations from evading liabilities through bankruptcy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Rhea-AI Summary

Pathalys Pharma, a late-stage biopharmaceutical company, has been established with seed financing from DaVita Venture Group and Catalys Pacific. The company focuses on chronic kidney disease (CKD) treatments, starting with the investigational drug upacicalcet, which has demonstrated efficacy in Japan. Pathalys plans to conduct two phase 3 clinical trials in the U.S. for upacicalcet to treat secondary hyperparathyroidism in hemodialysis patients. Neal Fowler, a former CEO at Liquidia, has been appointed as CEO, enhancing the leadership team's industry experience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $145.27 as of December 23, 2024.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 347.8B.

What are the main business segments of Johnson & Johnson?

Johnson & Johnson operates through three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products.

What recent developments have there been in Johnson & Johnson's pharmaceutical division?

Recently, Johnson & Johnson received expanded FDA approval for CARVYKTI®, a therapy for multiple myeloma, based on positive Phase 3 study results.

What products are included in Johnson & Johnson’s consumer health segment?

The consumer health segment includes products in baby care, beauty, oral care, over-the-counter drugs, and women's health.

What is CARVYKTI®?

CARVYKTI® is a one-time infusion therapy for multiple myeloma, recently approved for expanded use due to its efficacy in delaying disease progression.

What percentage of Johnson & Johnson's revenue is generated in the United States?

Over half of Johnson & Johnson’s total revenue is generated in the United States.

What is the focus of Johnson & Johnson’s medical devices segment?

The medical devices segment focuses on orthopedics, surgical instruments, and vision care.

What changes are happening with Johnson & Johnson’s consumer health division?

The consumer health division is being divested in 2023 and will operate under the new name Kenvue.

How does Johnson & Johnson contribute to global healthcare?

Johnson & Johnson develops innovative solutions to prevent, treat, and cure complex diseases, aiming to improve global health.

Where can I find more information about Johnson & Johnson?

More information about Johnson & Johnson can be found on their official website at www.jnj.com.

What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?

The pharmaceutical division focuses on immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases.

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Stock Data

347.83B
2.41B
0.09%
73.15%
0.73%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW BRUNSWICK